Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H35ClFN7O2 |
| Molecular Weight | 604.117 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC[C@H]1COC2=NC(N3CCN([C@@H](CC#N)C3)C(=O)C(F)=C)=C4CCN(CC4=N2)C5=C6C(Cl)=CC=CC6=CC=C5
InChI
InChIKey=PEMUGDMSUDYLHU-ZEQRLZLVSA-N
InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1
| Molecular Formula | C32H35ClFN7O2 |
| Molecular Weight | 604.117 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:17:10 GMT 2023
by
admin
on
Sat Dec 16 14:17:10 GMT 2023
|
| Record UNII |
8EOO6HQF8Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
756320
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8EOO6HQF8Y
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
KL-25
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
DB15568
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
138611145
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
Adagrasib
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
C157493
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | NCIT | ||
|
2326521-71-3
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
11519
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | INN | ||
|
8EOO6HQF8Y
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
DTXSID801336759
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY | |||
|
300000026691
Created by
admin on Sat Dec 16 14:17:10 GMT 2023 , Edited by admin on Sat Dec 16 14:17:10 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
Approved to target KRAS G12C mutations in the second-line setting,
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
the presence of strong CYP 3A4 inhibition by itraconazole can lead to an AUC increase of 400%.
MAJOR
|
||
|
TRANSPORTER -> INHIBITOR |
Reverses the multidrug resistance mediated by ABCB1 inhibits efflux.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
